CAPLIPOINT - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:02 am

IntraDay Trade Rating: 3.6

📊 Analysis: Caplin Point shows moderate intraday potential today. Current price (₹1,931) is below both 50DMA (₹1,970) and 200DMA (₹2,010), indicating short-term weakness. RSI at 43.7 suggests weak momentum, while MACD (-10.2) is negative, confirming bearish bias. Volume (30,932) is nearly equal to weekly average (31,016), showing stable but limited liquidity. Fundamentals remain strong with ROCE (28.6%) and ROE (22.0%), though valuation (P/E 42.0 vs industry PE 30.6) is stretched and quarterly profit declined slightly.

💹 Optimal Buy Price: Around ₹1,920–1,930 (near support zone).

🎯 Profit-Taking Levels: ₹1,950–1,970 (short-term resistance).

🛡️ Stop-Loss: ₹1,900 (below recent support).

⏱️ If Already Holding: Consider exiting if price fails to sustain above ₹1,935 with RSI dropping below 42 or MACD staying negative. Exit near ₹1,950–1,970 if momentum improves; cut positions if price slips below ₹1,900 with rising volume.

Positive

• 📈 Strong ROCE (28.6%) and ROE (22.0%).
• 💹 EPS at ₹46.0, showing earnings strength.
• 📊 FII holding increased (+0.35%).
• 📈 Debt-free balance sheet (Debt-to-equity 0.00).

Limitation

• ⚠️ Current price below both 50DMA and 200DMA.
• 📉 RSI at 43.7 indicates weak momentum.
• 📉 MACD (-10.2) shows bearish trend.
• ⚠️ P/E (42.0) higher than industry PE (30.6).

Company Negative News

• 📉 Quarterly PAT declined (₹103 Cr. vs ₹85.9 Cr. with -2.98% variation).
• 📉 DII holding reduced (-0.12%).

Company Positive News

• 📈 FII confidence with increased stake (+0.35%).
• 💹 Strong fundamentals with high ROCE and ROE.

Industry

• 🏭 Industry PE at 30.6, lower than Caplin Point’s valuation (42.0).
• 📊 Pharma sector supported by demand for generics and exports, though valuations remain sensitive.

Conclusion

⚖️ Caplin Point is a cautious intraday candidate today. Buy near ₹1,920–1,930, target ₹1,950–1,970, and protect downside at ₹1,900. If already holding, monitor RSI and MACD closely for exit signals. Strong fundamentals and FII support exist, but weak momentum and stretched valuation require strict risk management.

Would you like me to extend this into a peer benchmarking overlay against other mid-cap pharma players (like Alembic Pharma, Granules India, Laurus Labs) to compare intraday strength?